Welcome to Bio-Link
Bio-Link is a life sciences commercialisation company which facilitates partnerships based on technology review, project management, business development and deal negotiation. Bio-Link has offices in Sydney and Melbourne.
Our clients include Australian biotech companies and medical research institutes. Our portfolio extends across small molecule and peptide drug candidates, genetic and protein biomarkers, gene and cell therapies, immunotherapies and other leading technologies.
Bio-Link adds value to the commercialisation process through critical assessment of patents, packaging of pre-clinical and clinical data, technology marketing and identification and engagement with potential collaborators, licensees, or investors.
Our team has experience in therapeutics and diagnostics and has been involved in a number of commercial transactions in the USA, Europe and Australia.
Please explore this website to gain more information about our team, our stakeholders and our portfolio.
|
|
|
|
15th June 2009 - Bio-Link to Attend BioBanking 2009 in London, UK, 16th - 17th September
Dr Christian Toouli will be representing a number of different tissue bank and biomarker opportunities at this upcoming conference in London focused on the commercialisation of biobanks.
15th June 2009 - Bio-Link Engaged by Wesley Research Institute
Bio-Link has been engaged by the Wesley Research Institute to commercialise its Tissue Bank for the development of potential therapeutics and diagnostic technologies.
12th June 2009 - Bio-Link Engaged by the Howard Florey Institute
Bio-Link has been engaged to partner the IRAP (Insulin-regulated aminopeptidase) Drug Discovery Program of the Howard Florey Institute and St Vincent's Institute.
19th May 2009 - Bio-Link Engaged by Dairy Australia
Bio-Link has been engaged by Dairy Australia to assist in the commercialisation of a functional food technology.
28th January 2009 - Bio-Link Engaged by WAIMR and UWA
Bio-Link has been engaged by the Western Australian Institute for Medical Research and the University of Western Australia to provide business development services on behalf of the institutions' miRNA technology for cancer.
28th January 2009 - Bio-Link Engaged by QRxPharma Ltd.
Bio-Link as been engaged by QRxPharma to find drug development partners for its venom-derived coagulation modulators as potential therapeutic candidates to reduce blood loss and promote blood clotting.